Drug intelligence / Profile preview

BG2202

Development stage: Unknown
Lead developer: Guangzhou Bio-gene Technology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

BG2202 is an autologous CAR-T cell therapy that functions as an inhibitor of GPRC5D (G-protein coupled receptor family C group 5 member D). This therapeutic approach is designed to target and inhibit GPRC5D, a protein found on certain cancer cells, to elicit an anti-tumor response.

Targets

GPRC5D

Beyond the preview

Go deeper on BG2202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG2202.

Explore the full profile